DCM
EIGR

Dupont Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Dupont Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,246
Closed -$310K – 1805
2022
Q1 		$310K Buy
1,246
+483
+63% +$76.3K 0.01% 917
2021
Q4 		$119K Sell
763
-304
-28% -$58.8K ﹤0.01% 1260
2021
Q3 		$214K Buy
+1,067
New +$254K 0.01% 1215

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dupont Capital Management's EIGR Position: Q2 2022 in Review

Dupont Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 1,246 shares — an estimated $310K sold.

Dupont Capital Management first reported a position in EIGR in Q3 2021 and held it in 3 quarters. The position peaked at $310K in Q1 2022. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

  • Dupont Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Dupont Capital Management sold 1,246 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $310K.
  • Dupont Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2021 and held it in 3 quarters.
  • Dupont Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $310K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.